Similar articles

• Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.

  Gaglio P, Marfo K, Chiodo J 3rd. Gaglio P, et al. Dig Dis Sci. 2012 Nov;57(11):2774-85. doi: 10.1007/s10620-012-2276-3. Epub 2012 Jun 26. Dig Dis Sci. 2012. PMID: 22732834 Free PMC article. Review.
• Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

  Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Schrier RW, et al. N Engl J Med. 2006 Nov 16;355(20):2099-112. doi: 10.1056/NEJMoa065181. Epub 2006 Nov 14. N Engl J Med. 2006. PMID: 17105757 Clinical Trial.
• Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.

  Nemerovski C, Hutchinson DJ. Nemerovski C, et al. Clin Ther. 2010 Jun;32(6):1015-32. doi: 10.1016/j.clinthera.2010.06.015. Clin Ther. 2010. PMID: 20637957 Review.
• Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.

  Cárdenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH. Cárdenas A, et al. J Hepatol. 2012 Mar;56(3):571-8. doi: 10.1016/j.jhep.2011.08.020. Epub 2011 Oct 23. J Hepatol. 2012. PMID: 22027579 Clinical Trial.
• Tolvaptan for hyponatremia.

  Dawwas MF. Dawwas MF. N Engl J Med. 2007 Mar 1;356(9):961-2; author reply 962-3. N Engl J Med. 2007. PMID: 17338051 No abstract available.